Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bromopyruvate - PreScience Labs

Next Previous
Drug Profile

Bromopyruvate - PreScience Labs

Alternative Names: 3-bromopyruvate; 3-bromopyruvic acid; 3-BrPA; 3BP; KAT 3-BP; KAT-101; KAT-201; KAT/3BP; PSL-001

Latest Information Update: 23 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johns Hopkins University
  • Developer NewG Lab; PreScience Labs
  • Class Antineoplastics; Keto acids; Pyruvates; Small molecules
  • Mechanism of Action Alkylating agents; MASP2 protein inhibitors; Pyruvate dehydrogenase complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma; Skin cancer; Liver cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Pancreatic cancer
  • Preclinical Lymphoma
  • Discontinued Cancer

Most Recent Events

  • 05 Jun 2025 Primocure Pharma suspends a phase I/II trial in Pancreatic cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in South Korea (Intratumoural, PO) due to enrolment pause
  • 20 Dec 2023 Discontinued - Preclinical for Cancer in USA (Intra-arterial)
  • 20 Dec 2023 Pharmacodynamics data from preclinical studies in Pancreatic cancer released by PrimoCure Pharma (PrimoCure Pharma pipeline, December 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top